AR109859A1 - Inhibidor de bromodominio - Google Patents

Inhibidor de bromodominio

Info

Publication number
AR109859A1
AR109859A1 ARP170102935A ARP170102935A AR109859A1 AR 109859 A1 AR109859 A1 AR 109859A1 AR P170102935 A ARP170102935 A AR P170102935A AR P170102935 A ARP170102935 A AR P170102935A AR 109859 A1 AR109859 A1 AR 109859A1
Authority
AR
Argentina
Prior art keywords
methylsulfonylphenyl
cyclopropylmethoxy
methylisoquinolin
pharmaceutical composition
inhibitor
Prior art date
Application number
ARP170102935A
Other languages
English (en)
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of AR109859A1 publication Critical patent/AR109859A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe en la presente composiciones farmacéuticas del inhibidor del bromodominio 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona, que incluye sus formas cristalinas, formas amorfas, solvatos e hidratos. En algunas formas de realización, la composición farmacéutica comprende 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona que se procesó por micronización o dispersión secada por pulverización. En algunas formas de realización, la composición farmacéutica también comprende al menos un polímero. En algunas formas de realización, la composición farmacéutica comprende una matriz polimérica sólida que comprende 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona y al menos un polímero. Las composiciones farmacéuticas que comprenden 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilsoquinolin-1-ona son de utilidad para el tratamiento de cáncer o enfermedad neoplásica.
ARP170102935A 2016-10-20 2017-10-20 Inhibidor de bromodominio AR109859A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662410756P 2016-10-20 2016-10-20

Publications (1)

Publication Number Publication Date
AR109859A1 true AR109859A1 (es) 2019-01-30

Family

ID=62019669

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102935A AR109859A1 (es) 2016-10-20 2017-10-20 Inhibidor de bromodominio

Country Status (7)

Country Link
EP (1) EP3528810A4 (es)
JP (3) JP7129973B2 (es)
CN (1) CN110099685A (es)
AR (1) AR109859A1 (es)
AU (1) AU2017345468B2 (es)
TW (1) TW201821062A (es)
WO (1) WO2018075796A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
TW201642860A (zh) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑
CA3107050A1 (en) * 2018-07-23 2020-01-30 Celgene Quanticel Research, Inc. Process for the preparation of bromodomain inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048610A1 (en) * 2000-01-07 2002-04-25 Cima Michael J. High-throughput formation, identification, and analysis of diverse solid-forms
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US20160158246A1 (en) * 2013-08-06 2016-06-09 Oncoethix Gmbh Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor
US9884806B2 (en) * 2013-08-30 2018-02-06 Icahn School Of Medicine At Mount Sinai Cyclic vinylogous amides as bromodomain inhibitors
SI3290407T1 (sl) * 2013-10-18 2020-07-31 Celgene Quanticel Research, Inc Inhibitorji bromodomene
KR20160079823A (ko) 2013-11-27 2016-07-06 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 함유하는 제약 제제를 사용하여 백혈병을 치료하는 방법
TW201642860A (zh) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑
CN105732624B (zh) * 2016-01-28 2019-08-02 中国药科大学 吡咯[4,3,2-de]喹啉-2(1H)-酮类BRD4蛋白抑制剂的制备方法及其用途

Also Published As

Publication number Publication date
JP2019535671A (ja) 2019-12-12
CN110099685A (zh) 2019-08-06
EP3528810A4 (en) 2020-06-17
JP2022095897A (ja) 2022-06-28
TW201821062A (zh) 2018-06-16
EP3528810A1 (en) 2019-08-28
JP7129973B2 (ja) 2022-09-02
AU2017345468A1 (en) 2019-06-06
AU2017345468B2 (en) 2022-06-02
JP2024056905A (ja) 2024-04-23
WO2018075796A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
ECSP17071545A (es) Inhibidores de bromodominio
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
UY37098A (es) Moduladores de ror-gamma
UY37224A (es) Derivados aromáticos de sulfonamida
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
CL2019002810A1 (es) Compuestos inhibidores de ask1 y usos de los mismos.
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CR20190242A (es) Formas cristalinas de inhibidor de magl
AR109859A1 (es) Inhibidor de bromodominio
CL2019001337A1 (es) Formulaciones farmacéuticas.
AR114780A1 (es) Formulaciones estables de inmunoconjugado anti-cd79b
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
CL2018001590A1 (es) Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina.
CO2021007006A2 (es) Moduladores de la expresión de irf5
CL2017000178A1 (es) Compuestos para usar en el tratamiento antihelmíntico
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
CL2018001157A1 (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
ECSP18000689A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc
CU20190002A7 (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1 para el tratamiento del cáncer y composiciones farmacéuticas que los comprenden
CO2020003134A2 (es) Moduladores de la expresión de enac
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
CL2018003013A1 (es) Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con la enfermedad de parkinson.
BR112016026684A2 (pt) Fertilizante à base de enxofre

Legal Events

Date Code Title Description
FB Suspension of granting procedure